← All peptides

Peptide data sheet

Tirzepatide

Tirzepatide

GLP-1 · Mounjaro · Zepbound · LY3298176

Verdict

promising

The promising label reflects the large human trial program behind the branded prescription drugs Mounjaro and Zepbound; research-grade tirzepatide sold for lab use is not the same product and carries the gray-market sourcing risks the brand versions do not.

By MrPepTalks Editorial

Reviewed for scientific accuracy · research information, not medical advice

Last updated Reviewed

Quick answer

Tirzepatide is a dual GIP/GLP-1 receptor agonist commonly researched for weight and blood-sugar outcomes, with some of the strongest human trial data in its class. That data supported the FDA-approved prescription drugs Mounjaro and Zepbound for narrow indications; research-grade tirzepatide sold for lab use is not those products and is not FDA-approved. Gastrointestinal side effects are commonly reported, and the full safety picture outside supervised prescription use is still being studied.

At a glance
Class
Dual GIP / GLP-1 receptor agonist (synthetic peptide)
Half-life
roughly 5 days (reported)
FDA status
Mounjaro and Zepbound (tirzepatide) are FDA-approved for narrow indications (type 2 diabetes; chronic weight management).
WADA banned?
No

Which form actually works?

Brand injectable (Mounjaro / Zepbound)

Promising

The trial-backed prescription form the pivotal human studies used, dispensed as Mounjaro or Zepbound under medical supervision. It carries the most research context and the clearest safety monitoring of any form.

Research-grade / gray-market vial

Risky

Sold for laboratory research use only, this is not the studied prescription product. Purity, sterility, and labeled strength are not verified by any regulator, and mislabeled or contaminated material is a documented gray-market hazard that no vial reveals on sight.

Third-Party Testing & Certificate of Analysis (COA)

A certificate of analysis (COA) is a lab document that reports what a specific batch of material actually contains. Reputable research suppliers publish one for every batch, tied to a lot number you can match against the vial you received.

HPLC — purity
High-performance liquid chromatography reports purity as a percentage: how much of the sample is the intended compound rather than impurities.
Mass spectrometry (MS) — identity
Mass spectrometry confirms identity by measuring the sample's molecular mass, so it matches the peptide the label names.

It also matters who ran the test. In-house results come from the seller's own lab; an independent third-party lab has no stake in the result, so its COA generally carries more weight. Look for a named testing laboratory, a batch or lot number, and a test date that lines up with the vial in hand.

New to reading one? This guide walks through a COA line by line: how to read a peptide COA.

Sources

  1. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1), N Engl J Med 2022.
  2. Frías JP et al. Tirzepatide versus semaglutide once weekly in type 2 diabetes (SURPASS-2), N Engl J Med 2021.
  3. U.S. FDA Mounjaro (tirzepatide) prescribing information / approval, 2022.

Related peptides

All GLP-1

Frequently asked questions

Send it to me →

No spam. Compliant with CAN-SPAM (US), CASL (Canada) & GDPR (EU) · one-click unsubscribe. See our Privacy Policy.